Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo fol...

Detaylı Bibliyografya
Asıl Yazarlar:	Chakrabarti, S, Hale, G, Waldmann, H
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2004

Benzer Materyaller

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
Yazar:: Watson, C, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
Yazar:: Phuong-Thu T Pham, ve diğerleri
Baskı/Yayın Bilgisi: (2008-12-01)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1988)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
Yazar:: Clatworthy, MR, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Yazar:: Watson, C, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
Yazar:: Potter, M, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
Yazar:: Lv Meng, ve diğerleri
Baskı/Yayın Bilgisi: (2012-03-01)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
Yazar:: Fibbe, W, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

CAMPATH-1 antibodies in stem-cell transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Where do we go from here?
Yazar:: Rai, Vijesh
Baskı/Yayın Bilgisi: (2016)

Expert Systems: Where Are We? And Where Do We Go from Here?
Yazar:: Davis, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Editorial: Where Are We Now and Where Do We Go From Here
Yazar:: Gabriele Manganaro
Baskı/Yayın Bilgisi: (2022-01-01)

Availability of Campath-1 antibodies for bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
Yazar:: Maria Kadma da Silva Carriço, ve diğerleri
Baskı/Yayın Bilgisi: (2003-06-01)

Tractography: where do we go from here?
Yazar:: Jbabdi, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Afterword: Where Do We Go from Here?
Yazar:: Kimberly Vinall, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

Transplantation tolerance: the big picture. Where do we stand, where should we go?
Yazar:: Waldmann, H
Baskı/Yayın Bilgisi: (2017)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
Yazar:: Cull, G, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Commentary: Retinoblastoma management–Where are we and where do we go from here?
Yazar:: P Mahesh Shanmugam
Baskı/Yayın Bilgisi: (2020-01-01)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
Yazar:: Lundin, J, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

How Did We Get Here and Where are We Going?
Yazar:: Georgina CHAMBERS
Baskı/Yayın Bilgisi: (2022-09-01)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
Yazar:: Russell, N, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

CAMPATH-1H in inflammatory arthritis.
Yazar:: Watts, R, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

COVID-19 - where do we go from here?
Yazar:: Lee, Pei Hua, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Propriospinal myoclonus: where do we go from here?
Yazar:: Brown, P
Baskı/Yayın Bilgisi: (2014)

Oil prices : where do we go from here?/
Yazar:: 284295 Zanoyan, Vahan
Baskı/Yayın Bilgisi: (1986)

Math anxiety : where do we go from here? /
Yazar:: 297422 Hunt, Glen E.

Advanced ceramics : where do we go from here?/
Yazar:: 348668 Smith, Vincent, ve diğerleri

Multiple Sclerosis: Where do we go from here?
Yazar:: Marta Tejera-Alhambra, ve diğerleri
Baskı/Yayın Bilgisi: (2016-07-01)

Calibration research: Where do we go from here?
Yazar:: Linda eBol, ve diğerleri
Baskı/Yayın Bilgisi: (2012-07-01)

PITUITARY INCIDENTALOMAS – WHERE DO WE GO FROM HERE?
Yazar:: Syed Ali Imran
Baskı/Yayın Bilgisi: (2016-08-01)

Developmental Dyslexia: Where Do We Go from Here?
Yazar:: Paul E. Engelhardt
Baskı/Yayın Bilgisi: (2020-03-01)

OMR At Crossroads; Where Do We Go From Here ?
Yazar:: Mangala Meti
Baskı/Yayın Bilgisi: (2004-01-01)

Topological photonics: Where do we go from here?
Yazar:: Segev Mordechai, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
Yazar:: Chakrabarti, S, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Yazar:: Kottaridis, P, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

CAMPATH: from concept to clinic.
Yazar:: Waldmann, H, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Yazar:: Cull, G, ve diğerleri
Baskı/Yayın Bilgisi: (2000)